320 WEST 37TH STREET, NEW YORK, NY
Market cap: $5.3B (2/10/2026)
Price: $25.94
Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Immunovant, Inc. Completes $550 Million Underwritten Offering
Other Events
Michael Geffner, M.D. Departs as Chief Medical Officer of Immunovant
Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
Investor Presentation
Submission of Matters to a Vote of Security Holders
Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Free Writing Prospectus
Submission Upload
Correspondence